Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bisantrene - Race Oncology

Next Previous
Drug Profile

Bisantrene - Race Oncology

Alternative Names: Bisantrene-hydrochloride - Race Oncology; CL-216942; Cyabin; NSC-337766; Orange Crush; RC-110; RC-220; UPI-928; XANTRENE; Zantrene

Latest Information Update: 16 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth Pharmaceuticals
  • Developer Race Oncology; Sheba Medical Center; Wyeth Pharmaceuticals
  • Class Aldehydes; Anthracenes; Antineoplastics; Cytostatic antibiotics; Hydrazones; Imidazoles; Small molecules
  • Mechanism of Action DNA modulators; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Breast cancer
  • Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Solid tumours
  • Preclinical Lung cancer; Malignant melanoma; Renal cell carcinoma
  • Research Cancer

Most Recent Events

  • 02 Apr 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Australia (IV) (NCT06815575)
  • 03 Jan 2024 Phase-I/II clinical trials in Breast cancer (Metastatic disease, Combination therapy) (IV), prior to January 2024 (Race Oncology pipeline, January 2024)
  • 11 Dec 2023 Interim efficacy and adverse events data from a phase-II trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top